Use of Fc-engineered antibodies as clearing agents to increase contrast during PET

Rafal Swiercz, Srinivas Chiguru, Amir Tahmasbi, Saleh M. Ramezani, Guiyang Hao, Dilip K. Challa, Matthew A. Lewis, Padmakar V. Kulkarni, Xiankai Sun, Raimund J. Ober, Ralph P. Mason, E. Sally Ward

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Despite promise for the use of antibodies as molecular imaging agents in PET, their long in vivo half-lives result in poor contrast and radiation damage to normal tissue. This study describes an approach to overcome these limitations. Methods: Mice bearing human epidermal growth factor receptor type 2 (HER2)-overexpressing tumors were injected with radiolabeled (124I, 125I) HER2-specific antibody (pertuzumab). Pertuzumab injection was followed 8 h later by the delivery of an engineered, antibody-based inhibitor of the receptor, FcRn. Biodistribution analyses and PET were performed at 24 and 48 h after pertuzumab injection. Results: The delivery of the engineered, antibody-based FcRn inhibitor (or Abdeg, for antibody that enhances IgG degradation) results in improved tumor-to-blood ratios, reduced systemic exposure to radiolabel, and increased contrast during PET. Conclusion: Abdegs have considerable potential as agents to stringently regulate antibody dynamics in vivo, resulting in increased contrast during molecular imaging with PET. COPYRIGHT

Original languageEnglish (US)
Pages (from-to)1204-1207
Number of pages4
JournalJournal of Nuclear Medicine
Volume55
Issue number7
DOIs
StatePublished - Jul 1 2014

Fingerprint

Antibodies
Molecular Imaging
Injections
Neoplasms
Immunoglobulin G
Radiation
pertuzumab

Keywords

  • Breast cancer
  • Engineered antibodies
  • FcRn
  • PET

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Swiercz, R., Chiguru, S., Tahmasbi, A., Ramezani, S. M., Hao, G., Challa, D. K., ... Ward, E. S. (2014). Use of Fc-engineered antibodies as clearing agents to increase contrast during PET. Journal of Nuclear Medicine, 55(7), 1204-1207. https://doi.org/10.2967/jnumed.113.136481

Use of Fc-engineered antibodies as clearing agents to increase contrast during PET. / Swiercz, Rafal; Chiguru, Srinivas; Tahmasbi, Amir; Ramezani, Saleh M.; Hao, Guiyang; Challa, Dilip K.; Lewis, Matthew A.; Kulkarni, Padmakar V.; Sun, Xiankai; Ober, Raimund J.; Mason, Ralph P.; Ward, E. Sally.

In: Journal of Nuclear Medicine, Vol. 55, No. 7, 01.07.2014, p. 1204-1207.

Research output: Contribution to journalArticle

Swiercz, Rafal ; Chiguru, Srinivas ; Tahmasbi, Amir ; Ramezani, Saleh M. ; Hao, Guiyang ; Challa, Dilip K. ; Lewis, Matthew A. ; Kulkarni, Padmakar V. ; Sun, Xiankai ; Ober, Raimund J. ; Mason, Ralph P. ; Ward, E. Sally. / Use of Fc-engineered antibodies as clearing agents to increase contrast during PET. In: Journal of Nuclear Medicine. 2014 ; Vol. 55, No. 7. pp. 1204-1207.
@article{8c06015242ed443d9c511a29e25cc3db,
title = "Use of Fc-engineered antibodies as clearing agents to increase contrast during PET",
abstract = "Despite promise for the use of antibodies as molecular imaging agents in PET, their long in vivo half-lives result in poor contrast and radiation damage to normal tissue. This study describes an approach to overcome these limitations. Methods: Mice bearing human epidermal growth factor receptor type 2 (HER2)-overexpressing tumors were injected with radiolabeled (124I, 125I) HER2-specific antibody (pertuzumab). Pertuzumab injection was followed 8 h later by the delivery of an engineered, antibody-based inhibitor of the receptor, FcRn. Biodistribution analyses and PET were performed at 24 and 48 h after pertuzumab injection. Results: The delivery of the engineered, antibody-based FcRn inhibitor (or Abdeg, for antibody that enhances IgG degradation) results in improved tumor-to-blood ratios, reduced systemic exposure to radiolabel, and increased contrast during PET. Conclusion: Abdegs have considerable potential as agents to stringently regulate antibody dynamics in vivo, resulting in increased contrast during molecular imaging with PET. COPYRIGHT",
keywords = "Breast cancer, Engineered antibodies, FcRn, PET",
author = "Rafal Swiercz and Srinivas Chiguru and Amir Tahmasbi and Ramezani, {Saleh M.} and Guiyang Hao and Challa, {Dilip K.} and Lewis, {Matthew A.} and Kulkarni, {Padmakar V.} and Xiankai Sun and Ober, {Raimund J.} and Mason, {Ralph P.} and Ward, {E. Sally}",
year = "2014",
month = "7",
day = "1",
doi = "10.2967/jnumed.113.136481",
language = "English (US)",
volume = "55",
pages = "1204--1207",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "7",

}

TY - JOUR

T1 - Use of Fc-engineered antibodies as clearing agents to increase contrast during PET

AU - Swiercz, Rafal

AU - Chiguru, Srinivas

AU - Tahmasbi, Amir

AU - Ramezani, Saleh M.

AU - Hao, Guiyang

AU - Challa, Dilip K.

AU - Lewis, Matthew A.

AU - Kulkarni, Padmakar V.

AU - Sun, Xiankai

AU - Ober, Raimund J.

AU - Mason, Ralph P.

AU - Ward, E. Sally

PY - 2014/7/1

Y1 - 2014/7/1

N2 - Despite promise for the use of antibodies as molecular imaging agents in PET, their long in vivo half-lives result in poor contrast and radiation damage to normal tissue. This study describes an approach to overcome these limitations. Methods: Mice bearing human epidermal growth factor receptor type 2 (HER2)-overexpressing tumors were injected with radiolabeled (124I, 125I) HER2-specific antibody (pertuzumab). Pertuzumab injection was followed 8 h later by the delivery of an engineered, antibody-based inhibitor of the receptor, FcRn. Biodistribution analyses and PET were performed at 24 and 48 h after pertuzumab injection. Results: The delivery of the engineered, antibody-based FcRn inhibitor (or Abdeg, for antibody that enhances IgG degradation) results in improved tumor-to-blood ratios, reduced systemic exposure to radiolabel, and increased contrast during PET. Conclusion: Abdegs have considerable potential as agents to stringently regulate antibody dynamics in vivo, resulting in increased contrast during molecular imaging with PET. COPYRIGHT

AB - Despite promise for the use of antibodies as molecular imaging agents in PET, their long in vivo half-lives result in poor contrast and radiation damage to normal tissue. This study describes an approach to overcome these limitations. Methods: Mice bearing human epidermal growth factor receptor type 2 (HER2)-overexpressing tumors were injected with radiolabeled (124I, 125I) HER2-specific antibody (pertuzumab). Pertuzumab injection was followed 8 h later by the delivery of an engineered, antibody-based inhibitor of the receptor, FcRn. Biodistribution analyses and PET were performed at 24 and 48 h after pertuzumab injection. Results: The delivery of the engineered, antibody-based FcRn inhibitor (or Abdeg, for antibody that enhances IgG degradation) results in improved tumor-to-blood ratios, reduced systemic exposure to radiolabel, and increased contrast during PET. Conclusion: Abdegs have considerable potential as agents to stringently regulate antibody dynamics in vivo, resulting in increased contrast during molecular imaging with PET. COPYRIGHT

KW - Breast cancer

KW - Engineered antibodies

KW - FcRn

KW - PET

UR - http://www.scopus.com/inward/record.url?scp=84904120482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904120482&partnerID=8YFLogxK

U2 - 10.2967/jnumed.113.136481

DO - 10.2967/jnumed.113.136481

M3 - Article

VL - 55

SP - 1204

EP - 1207

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 7

ER -